St. Jude shared a post on X:
“St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with MYC, a cancer-driving protein.
The findings present RBM5 as an attractive target for more precise, lower-toxicity treatments.”
Other articles about leukemia on OncoDaily.